NEW YORK, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a
class action lawsuit has been filed Trevena, Inc. (“Trevena” or the “Company”) (NASDAQ: TRVN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired
Trevena securities between May 2, 2016 and October 8, 2018, inclusive (the "Class Period"). Such investors are encouraged
to join this case by visiting the firm’s site: www.bgandg.com/trvn.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws
under the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants misled shareholders to believe that the April 28,
2016 End-of-Phase 2 Meeting with the United States Food and Drug Administration (“FDA”) was more successful than it really
was. On May 2 2016, Trevena published a report, “Trevena Announces Successful End-of-Phase 2 Meeting with FDA and Outlines Phase 3
Program for Oliceridine,” and said that it had “reached general agreement” with the FDA on key elements of its Phase 3 program for
oliceridine (TRV130) and was “very pleased” with the FDA discussions and outcome. However, on October 9, 2018, information from the
Company and the FDA’s April 28, 2016 meeting were released and showed that the FDA: (1) “did not agree with the proposed dosing in
the Phase 3 studies”; (2) “did not agree with the proposed primary endpoint”; and (3) “did not agree with the proposed
non-inferiority (NI) margin for comparing morphine to oliceridine.” Following this news, Trevena stock dropped $2.04 per
share, or over 68%, over the next two trading days to close at $0.947 per share on October 10, 2018.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site:
www.bgandg.com/trvn or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst,
Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Trevena you have until December 10,
2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you
serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class
action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
